Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Parisi

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
The Lancet. Oncology|June 6, 2022
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J Pinato, Juan Aguilar-Company, Daniela Ferrante, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
The Lancet. Oncology|March 10, 2023
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registryAlessio Cortellini, Josep Tabernero, Uma Mukherjee, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
The Lancet. Oncology|June 6, 2022
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J Pinato, Juan Aguilar-Company, Daniela Ferrante, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
The Lancet. Oncology|March 10, 2023
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registryAlessio Cortellini, Josep Tabernero, Uma Mukherjee, et al.
Pageof 11